68-6

66/104

630Okamatsu-Haga C, Suzuki M, Radulovic V, van der Garde M, Koide S, Soboleva S, Gåfvels M, Nittono H, Ohara A, Miharada K: Induc-tion of blood-circulating bile acids supports recovery from myelosuppressive chemo-therapy. Blood Advance, 2020; 12: 1833-1843. 41) Zen Y, Kondou H, Nakazawa A, Tanikawa K, Hasegawa Y, Bessho K, Imagawa K, Ishige T, Inui A, Suzuki M, Kasahara M, Yamamoto K, Yoshioka T, Kage M, Hayashi H: Proposal of a liver histology-based scoring system for bile salt export pump deficiency. Hepatol Res, 2020; 50: 754-762. 42) Kakiyama G, Marques D, Martin R, Takei H, Rodriguez-Agudo D, LaSalle SA, Shibasaki Y, Liu X, Green R, Erickson S, Gil G, Fuchs M, Suzuki M, Nittono H, Hylemon PB, Zhou H, Pandak WM: Insulin resistance mediated Cyp7b1 dysregulation leads to accumulation of cholesterol metabolites that drive NAFL to NASH. Lipid Res, 2020; 61: 1629-1644. 43) Sato K, Kakiyam G, Suzuki M, Naritaka N, Takei H, Sato H, Kimura A, Murai T, Kuro-sawa T, Pandak WM. Nittono H, Shimizu T: Changes in conjugated urinary bile acids in children across age groups. Steroids, 2020; 164: 108730. 44) Suganuma H, Bonney D, Andersen CC, McPhee AJ, Sullivan TR, Gibson RA, Collins CT: The efficacy and safety of peripheral intravenous parenteral nutrition vs 10% glucose in preterm infants born 30 to 33 weeks’ gestation: a randomised controlled trial. BMC Pediatr, 2020; 20: 384. 45) Suganuma H, McPhee AJ, Collins CT, Liu G, Leemaqz S, Andersen CC, Ikeda N, Ohkawa N, Taha AY, Gibson RA: Intravenous fat induces changes in PUFA and their bioactive metabolites: Comparison between Japanese and Australian preterm infants. Prostaglan-dins Leukot Essent Fatty Acids, 2020; 156: 102026. 46) Nishizaki N, Hara T, Obinata K, Nakagawa M, Shimizu T: Clinical effects and outcomes after polymyxin b-immobilized fiber column direct hemoperfusion treatment for septic shock in preterm neonates. Pediatr Crit Care Med, 2020; 21: 156-163. 47) Nishizaki N, Matsuda A, Yoneyama T, Wata-nabe A, Obinata K, Shimizu T: The influence on renal function of ibuprofen treatment for patent ductus arteriosus in extremely low birthweight infants. Pediatr Int, 2020; 62: 193-199. 48) Ogyu A, Chan O, Littmann J, Pang HH, Lining X, Liu P, Matsunaga N, Ohmagari N, fukuda K, Wernli D: National action to combat AMR: A One-Health approach to assess policy priorities in action plans. BMJ Glob Heal, 2020; 5: e002427. 49) Hayakawa K, Kutsuna S, Kawamata T, Sugiki Y, Nonaka C, Tanaka K, Shoji M, Nagai M, Tezuka S, Shinya K, Saito H, Harada T, Moriya N, Tsuboi M, Norizuki M, Sugiura Y, Osanai Y, Sugiyama M, Okuhama J, Kanda K, Wakimoto Y, Ujiie M, Morioka S, Yamamoto K, Kinoshita N, Ishikane M, Saito S, Mori-yama Y, Ota M, Nakamura K, Nakamoto T, Ide S, Nomoto H, Akiyama Y, Suzuki T, Miyazato Y, Gu Y, Matsunaga N, Tsuzuki S, Fujitomo Y, Kusama Y, Shichino H, Kane-shige M, Yamanaka J, Saito M, Hojo M, Hashimoto M, Izumi S, Takasaki J, Suzuki M, Sakamoto K, Hiroi Y, Emoto S, Tokuhara M, Kobayashi T, Tomiyama K, Nakamura F, Ohmagari N, Sugiyama H: SARS-CoV-2 infection among returnees on charter flights to Japan from Hubei, China: a report from National Center for Global Health and Medi-cine. Glob Health Med, 2020; 2: 107-111. 50) Tsuzuki S, Matsunaga N, Ohmagari N: Road to comprehensive estimation of antimicrobial resistance (AMR) disease burden in Japan． Glob Health Med, 2020; 2: 164-167. 51) Tsuzuki S, Matsunaga N, Yahara K, Gu Y, Hayakawa K, Hirabayashi A, Kajihara T, Sugai M, Shibayama K, Ohmagari N: National trend of blood-stream infection attributable deaths caused by Staphylococcus aureus and Escherichia coli in Japan. J Infect Chemother, 2020; 26: 367-371. 52) Takaya S, Hayakawa K, Matsunaga N, Mori-yama Y, Katanami Y, Tajima T, Tanaka C, Kimura Y, Saito S, Kusama Y, Morioka S, Fujimoto Y, Ohmagare N: Surveillance systems for healthcare-associated infection in high and upper-middle income countries: A scoping review. J Infect Chemother, 2020; 26: 429-437.